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Abstract
While treatment for testicular cancer (TC) has become standardized after the 1980s with an
associated significant improvement in patient survival, this has been accompanied by an
increased risk of second primary cancers (SPCs). Patients were identified from the Swedish
Cancer Registry spanning the years from 1980 to 2015, including 8788 individuals with pri-
mary TC and their SPCs. Relative risks (RRs) for SPC were calculated using the general-
ized Poisson regression model. SPCs were diagnosed in 9.4% of patients with TC and half
of them were late onset cancers not common in the population in their 40s. Overall RR of
SPCs (excluding second TC) was 1.30 (95%CI: 1.20–1.40), including high risks for seven
solid cancers, non-Hodgkin lymphoma and leukemia. Second TC was the most common
SPC and the RR of 17.19 (95%CI: 14.89–19.85) was the highest recorded. Cancers known
to be fatal as first primary cancers were also fatal as SPC in TC patients. Survival at 30
years of follow-up was approximately 80% for TC patients without SPC but it decreased to
40% for patients with SPC. The unexpected finding that half of the identified SPCs were
typical late onset cancers in the middle-aged population raises concerns that therapy may
facilitate premature aging. The risks of SPC are clinically important for the long-term man-
agement of TC patients and the high-mortality calls for a future management strategy.
Introduction
Testicular cancers (TCs) are predominantly germ cell tumors of two main types, seminomas
and non-seminomas, the latter including teratoma and embryonal tumor as the largest histo-
logical types [1]. The incidence of testicular cancer has increased in many countries, and it is
highest in developed countries and lowest in developing countries [2]. In Europe, the
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incidence of TC has dramatically increased with an equally dramatic decrease in mortality [3,
4]. The 5-year relative survival in Europe and USA around the year 2005 was close to 99% for
seminoma and 94% for non-seminoma [5]. Aberrant fetal gonocytes are precursor lesions of
TC constituting in-situ lesions, which gain invasive phenotype usually in early adulthood [6,
7]. Individual risk factors of TC include genital malformations such as cryptorchidism, hypo-
spadias and inguinal hernia; in addition, subfertility and some birth-related factors have also
been associated with TC [8–10].
The dramatic decrease in mortality concerning TC is one of the success stories of cancer
treatment [11]. It was achieved through several discoveries, including therapeutic effects of cis-
platin in the1960s and adoption of BEP (bleomycin, etoposide and cisplatin) regimen in the
1980s [11]. The treatment depends on whether the disease is localized or metastatic, including
orchiectomy and BEP and, in addition, radiation for seminoma that is radiosensitive [12].
Radiation and chemotherapy agents in BEP are DNA-damaging and concerns of second pri-
mary cancers (SPCs) have been relevant [13]. It was estimated that the risk of SPCs increases
2.6-fold after subdiaphragmatic radiotherapy and 2.1-fold after chemotherapy when the
median follow-up time was 17.6 years [14]. This was in-line with a more recent study with a
median follow-up of 14.4 years; more than one line of treatments increased the risk of SPCs to
3.7 [15]. According to a qualitative risk estimation conducted by the International Agency for
Research on Cancer ‘there is sufficient evidence in humans for the carcinogenicity of etoposide
in combination with cisplatin and bleomycin. Etoposide in combination with cisplatin and
bleomycin causes acute myeloid leukaemia’ [16]. In view of the known relative short ‘latency
time’ for acute myeloid leukemia compared to solid tumors, it is relevant to consider possible
risks for even solid tumors in TC patients when follow-up times are becoming longer [17, 18].
A recent study reported a 25-year cumulative incidence of solid SPC at 10.3% [19]. In nonse-
minoma patients increased risks were noted for SPCs of the thyroid, lung, stomach, pancreas,
colon, and bladder and of melanoma and soft tissue sarcoma while the risks among seminoma
patients covered the small intestine, pancreas, and urinary bladder.
We conducted here a nationwide Swedish study on survivors of TC diagnosed after 1980
when the successful therapies were introduced. Causes of death were considered in patients
with and without SPCs. This is an extension of our study published in 2010 focusing only on
the risk of SPC with a sample size of 40% of the present numbers [20]. Even if we have no data
on the therapies applied, which is a weakness compared to some previous studies, we are able
to show novel features of SPC and the related mortality [21–23].
Subjects and methods
The Swedish Family-Cancer Database was used to estimate the familial relative risks of the
major identifiable malignancies in the Swedish population. This database was created by link-
ing information from the Multi-Generation Register, national censuses, Swedish Cancer Reg-
istry and death notifications [24]. The linkages were conducted at the National Board for
Health and Welfare using the personal identifiers, which were removed before delivery of the
datasets to the users. The 2015 update of these data includes a total population of over 16.1 mil-
lion individuals. The Swedish Cancer Registry requires the compulsory reporting of all diag-
nosed malignancies and provides more than 90% coverage of all cancer diagnoses in Sweden
[25]. The registry relies on separate compulsory notifications from clinicians and pathologists/
cytologists who diagnosed the neoplasms [26]. The registry counts tumors, not patients, except
for skin and urinary tract tumors diagnosed at the same topological area (https://www.ancr.
nu/dyn/resources/File/file/7/4247/1412940269/total_document_survey_optimeret.pdf). To
classify cancer types, the Swedish Cancer Register has used the following International
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since 1993, and ICD-O/3 since 2005. The degree of histological verification of TC has been
close to 100% [27]. In addition to seminoma and non-seminoma, some rare undefined histolo-
gies (<2% of all cases) were not included in the histology-specific analyses; this was the only
exclusion criteria applied and the reason why the total number to patients was somewhat
higher than the sum of patients with seminoma and nonseminoma. Laterality of TC was not
available. An ad hoc study on the diagnostic accuracy of second neoplasms in the Swedish Can-
cer Registry found 98% to be correctly classified; no recorded SPC was found to be a metastasis
upon reexamination [28].
Relative risks (RRs) were assessed with incidence rate ratios, regressed over a fixed effects
generalized Poisson model. RRs for SPC were obtained by comparing incidence rates for SPC
X in TC patients with rates for first cancer X in the background population. Follow-up was
started at diagnosis of TC after January 1, 1980 and terminated at diagnosis of SPC, emigra-
tion, death or December 31, 2015, whichever occurred first. Identical follow-up times were
applied when TC was considered as SPC. Sex (for cancers in both sexes), age group, calendar-
period, socioeconomic status and residential areas were treated as potential confounders and
were adjusted for in the regression model. Confidence intervals (CIs) were calculated for 5%
level of significance. For survival analysis multivariate Cox-proportional hazard regression was
used (adjustments as above) and Kaplan-Meier curves were generated to depict survival proba-
bilities stratified over SPC diagnosis.
All cancer-related deaths were stratified into TC, SPC, higher order primaries, ‘other can-
cer’ and non-neoplastic cause of death. Higher order primaries were 3nd, 4th etc primary can-
cers. ‘Other cancer’ includes cases diagnosed at the issue of death certificates, referred to as
‘death certificate notifications’ [26]. These death notifications are not used by the Swedish
Cancer Registry to complement cancer data, opposite to the other Nordic Cancer Registries
[25, 26]. We have found that the notifications often included multiple cancers and cancer of
unknown primary (CUP). As CUP is a metastatic cancer, even other listed cancers, if not those
reported to the Cancer Registry, may be metastases [29]. If the death certificate notification
matched the organ site of the reported primary cancer it was classified to that site but in most
cases such a reclassification could not be made and the classification was to ‘other neoplasia’.
All the above statistical analyses were done with SAS version 9.4.
The study was approved by the Ethical Review Board of Lund University (Reg.nr 2012/
795), Sweden and conducted in accordance with the tenets of the Declaration of Helsinki.
Results
The Family-Cancer Database included 8788 TCs of which 4879 were seminomas and 3717
non-seminomas diagnosed since the year 1980 (Table 1). The respective number of SPCs after
these cancers were 830 (9.4%), 568 (11.6%) and 249 (6.7%), for which the median follow-up
times were 11, 11 and 13 years respectively.
Risks for SPCs are shown in Table 2 after TCs. Cancers are listed when at least three SPCs
were diagnosed after TC. The most common SPCs were TC and prostate cancer. The RR for
second TC was 17.19 (95%CI: 14.89–19.85), and 2.1% of TC patients were afflicted with a sec-
ond TC. Overall RR for SPC (excluding TC) after TC was 1.30 (95%CI: 1.20–1.40). Risks for a
total of nine non-TC SPCs were increased; the highest increases being for thyroid gland (2.64,
95%CI: 1.32–5.29) and connective tissue (2.60, 95%CI: 1.40–4.84) cancer. Some typically old
age cancers were common as SPCs, prostate cancer (1.16, 95%CI: 1.00–1.36) accounting for 1/
4 of all cases (the median age of onset for prostate cancer was 64 years). Others were stomach,
esophageal, liver, bladder and skin (squamous cell) cancers, which combined accounted for
Second cancer
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Table 2. RRs of second primary cancers in survivors of testicular cancer.
Second cancer site After testicular cancer
Cases RR1 95%CI2
All (excluding testis) 639 1.30 1.20–1.40
Upper aerodigestive tract 12 0.78 0.45–1.38
Esophagus 9 1.58 0.82–3.03
Stomach 16 1.40 0.86–2.29
Small intestine 3 1.15 0.37–3.58
Colorectum 67 1.33 1.05–1.69
Liver 12 1.25 0.71–2.21
Pancreas 14 1.40 0.83–2.36
Lung 36 0.98 0.71–1.36
Prostate 161 1.16 1.00–1.36
Testis 191 17.19 14.89–19.85
Other male genital 4 2.11 0.79–5.63
Kidney 32 2.19 1.55–3.10
Urinary bladder 53 1.78 1.36–2.33
Melanoma 33 1.13 0.80–1.58
Skin, squamous cell 32 1.52 1.07–2.15
Eye 3 1.93 0.62–6.00
Nervous system 24 1.37 0.92–2.05
Thyroid gland 8 2.64 1.32–5.29
Endocrine glands 8 1.10 0.55–2.19
Connective tissue 10 2.60 1.40–4.84
Non-Hodgkin lymphoma 36 1.87 1.35–2.59
Hodgkin lymphoma 3 0.98 0.32–3.04
Myeloma 9 1.36 0.71–2.62
Leukemia 31 1.99 1.40–2.83
Acute myeloid leukemia 10 3.59 1.93–6.67
Chronic myeloid leukemia 5 3.07 1.27–7.39
Acute lymphoid leukemia 3 3.58 1.15–11.13
Chronic lymphoid leukemia 7 1.29 0.62–2.71
Others 6 1.54 0.69–3.42
CUP3 18 1.55 0.98–2.47
RR1 = relative risk, 95%CI2 = 95% confidence interval, bold font indicates that the lower limit of 95%CI does not
include 1.00. CUP3 = cancer of unknown primary.
https://doi.org/10.1371/journal.pone.0214410.t002
Table 1. The number and age at diagnosis of patients with testicular cancer and number of patients with second
primary cancer.
Testicular cancer histology N (%) Median age at diagnosis IQR1(years)
Testicular cancer 8788 (100.0) 34 (27–42)
Seminoma 4879 (55.5) 38 (31–45)
Non-seminoma 3717 (42.3) 29 (24–36)
SPC2s following testicular cancer N (%) Median follow-up time IQR (years)
Testicular cancer 830 (9.4) 11 (4–19)
Seminoma 568 (11.6) 11 (4–19)
Non-seminoma 249 (6.6) 13 (4–20)
IQR1 = Interquartile range (lower quartile-upper quartile)
SPC2 = second primary cancer
https://doi.org/10.1371/journal.pone.0214410.t001
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another 1/4 of all cases. RRs were over 1.00 for all of them, and these were significant for pros-
tate (1.16, 95%CI: 1.00–1.36), bladder (1.78, 95%CI: 1.36–2.33) and skin (1.52, 95%CI: 1.07–
2.15) cancers. The RR for these six cancers combined was 1.35 (N = 283, 95%CI: 1.21–1.49).
For subtypes of leukemia, risks for acute and chronic myeloid leukemia and acute lymphoid
leukemia were increased (all RRs over 3.00).
In Table 3 data were analyzed by follow-up of less than five years or more than five years;
the overall RRs were 1.52 (95%CI: 1.26–1.83) and 1.55 (95%CI: 1.42–1.68). Risks for colorectal,
bladder and connective tissue cancers and non-Hodgkin lymphoma were only increased in
the long follow-up period, while risks for other male genital, kidney, skin (squamous cell) and
thyroid cancers, myeloma and CUP were only increased in the first period. Leukemia risk was
increased in both periods, more in the first period (3.65 vs 1.73) when the RR for acute myeloid
leukemia reached 6.56 (95%CI: 2.46–17.50).
Table 3. Relative risks (RRs) of second primary cancers in survivors of testicular cancer by follow-up time.
Second cancer site <5 yrs. > = 5 yrs.
Cases RR1 95%CI2 Cases RR 95%CI
All (excluding testis) 109 1.52 1.26–1.83 530 1.55 1.42–1.68
Upper aerodigestive tract 0 - - - - 12 0.94 0.54–1.66
Esophagus 1 1.32 0.19–9.39 8 1.65 0.82–3.30
Stomach 3 1.21 0.39–3.76 13 1.42 0.83–2.45
Small intestine 0 - - - - 13 1.39 0.45–4.32
Colorectum 3 0.33 0.11–1.04 64 1.51 1.18–1.93
Liver 0 - - - - 12 1.52 0.86–2.68
Pancreas 3 1.60 0.52–4.97 11 1.32 0.73–2.39
Lung 4 0.60 0.23–1.60 32 1.04 0.74–1.48
Prostate 24 1.22 0.82–1.82 137 1.13 0.96–1.34
Testis 111 25.51 21.15–30.77 80 11.86 9.51–14.79
Other male genital 2 7.12 1.78–28.50 2 1.27 0.32–5.09
Kidney 16 5.70 3.49–9.31 16 1.32 0.81–2.16
Urinary bladder 5 0.96 0.40–2.32 48 1.92 1.44–2.54
Melanoma 6 1.01 0.45–2.24 27 1.13 0.77–1.65
Skin, squamous cell 6 2.24 1.01–4.99 26 1.45 0.99–2.13
Eye 0 - - - - 3 2.36 0.76–7.34
Nervous system 7 1.63 0.78–3.42 17 1.26 0.78–2.03
Thyroid gland 4 5.14 1.93–13.70 4 1.73 0.65–4.62
Endocrine glands 3 1.81 0.58–5.62 5 0.87 0.36–2.08
Connective tissue 1 1.42 0.20–10.05 9 2.99 1.55–5.75
Non-Hodgkin lymphoma 7 1.84 0.88–3.86 29 1.83 1.27–2.64
Hodgkin lymphoma 0 - - - - 3 1.45 0.47–4.50
Myeloma 3 3.23 1.04–10.02 6 1.08 0.49–2.41
Leukemia 9 3.65 1.90–7.02 22 1.73 1.14–2.63
Acute myeloid leukemia 4 6.56 2.46–17.50 6 2.76 1.24–6.14
Chronic myeloid leukemia 1 2.30 0.32–16.38 4 3.35 1.26–8.95
Acute lymphoid leukemia 0 - - - - 3 5.23 1.68–16.28
Chronic lymphoid leukemia 1 1.11 0.16–7.86 6 1.33 0.60–2.97
Others 3 4.14 1.34–12.85 3 0.94 0.30–2.93
CUP3 1 0.45 0.06–3.17 17 1.78 1.11–2.87
RR1 = relative risk, 95%CI2 = 95% confidence interval, bold font indicates that the lower limit of 95%CI does not include 1.00, CUP3 = cancer of unknown primary.
https://doi.org/10.1371/journal.pone.0214410.t003
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SPC risk was higher after non-seminoma (1.43, 95%CI: 1.24–1.66) than after seminoma
(1.28, 95%CI: 1.16–1.40) (Table 4). For second TC the order was reversed, RR being higher
after seminoma (23.30, 95%CI: 19.49–27.86) compared to non-seminoma (11.61, 95%CI:
9.11–14.80, note non-overlapping 95%CIs); second TC was diagnosed in 2.5% of seminoma
patients and in 1.8% of non-seminoma patients. While risks for kidney, bladder and connec-
tive tissue cancers and leukemia were high in both types of TC, esophageal and thyroid cancers
and non-Hodgkin lymphoma were in excess only after seminoma and colorectal cancer only
after non-seminoma. However, because of the small case numbers the 95% CIs were wide and
overlapping.
In TC without SPC, non-neoplastic causes were the most common cause of death (52.3%)
and TC ranked the second (39.4%) (Table 5). However, these percentages were reversed in
seminoma (71.2% vs. 21.6%) compared to non-seminoma (33.9% vs. 59.2%), (P<0.0001). In
TC with SPC, non-TC SPCs were the main cause of death overall (52.3%), in seminoma
(52.2%) as well as in non-seminoma (54.2%). Non-neoplastic causes ranked second (23.5% in
all TC), followed by other cancers (13.2%), higher order primaries (i.e., 3nd, 4th etc primary
Table 4. RRs of second primary cancers after seminoma and non-seminoma.
Second cancer site Seminoma Non-seminoma
Cases RR1 95%CI2 Cases RR 95%CI
All (excluding testis) 445 1.28 1.16–1.40 183 1.43 1.24–1.66
Upper aerodigestive tract 8 0.75 0.37–1.50 4 0.89 0.34–2.38
Esophagus 9 2.17 1.13–4.18 0 - - - -
Stomach 14 1.67 0.99–2.82 2 0.72 0.18–2.88
Colorectum 46 1.26 0.94–1.68 21 1.64 1.07–2.51
Liver 9 1.30 0.67–2.49 3 1.22 0.39–3.78
Pancreas 12 1.64 0.93–2.89 2 0.79 0.20–3.16
Lung 21 0.79 0.51–1.21 15 1.62 0.98–2.69
Prostate 115 1.11 0.92–1.33 38 1.22 0.88–1.67
Testis 123 23.30 19.49–27.86 66 11.61 9.11–14.80
Kidney 23 2.22 1.48–3.34 9 2.20 1.15–4.23
Urinary bladder 34 1.57 1.12–2.19 19 2.57 1.64–4.03
Melanoma 22 1.15 0.76–1.74 9 1.10 0.61–1.98
Skin, squamous cell 21 1.35 0.88–2.08 11 1.87 0.97–3.59
Eye 3 2.87 0.92–8.90 0 - - - -
Nervous system 17 1.53 0.95–2.46 7 1.12 0.53–2.34
Thyroid gland 6 3.19 1.43–7.10 2 1.75 0.44–7.01
Endocrine glands 7 1.48 0.70–3.10 0 - - - -
Connective tissue 6 2.39 1.07–5.32 4 3.08 1.16–8.23
Non-Hodgkin lymphoma 26 1.96 1.33–2.88 10 1.73 0.93–3.21
Myeloma 5 1.05 0.44–2.51 4 2.36 0.89–6.29
Leukemia 21 1.96 1.28–3.00 10 2.16 1.16–4.02
Acute myeloid leukemia 8 4.27 2.13–8.55 2 2.42 0.60–9.68
Chronic myeloid leukemia 2 2.01 0.50–8.06 3 5.01 1.61–15.56
Acute lymphoid leukemia 2 4.42 1.10–17.71 1 2.73 0.38–19.38
Chronic lymphoid leukemia 6 1.55 0.69–3.45 1 0.75 0.10–5.29
Others 3 1.14 0.37–3.53 3 2.62 0.84–8.12
CUP3 12 1.44 0.82–2.53 6 1.99 0.89–4.43
RR1 = relative risk, 95%CI2 = 95% confidence interval, bold font indicates that the lower limit of 95%CI does not include 1.00. CUP3 = cancer of unknown primary.
https://doi.org/10.1371/journal.pone.0214410.t004
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cancers, 6.3%) and TC (first or SPC combined, 4.6%). ‘Other cancers’ were reported in death
certificates but had not been reported to the Cancer Registry (see Methods).
Causes of death in TC patients are listed according to the type of SPC (Table 6). Sites were
included when at least four deaths occurred. When the SPC was a known fatal cancer, such as
pancreatic, esophageal and liver cancer, all patients died because of the SPC. Even for colorec-
tal and lung cancers as SPC the cause of death was SPC in more than 80% of cases. No patient
died of skin cancer when this was the SPC.
The survival probabilities for TC patients are shown in Fig 1, including TC without SPC,
TC with TC as SPC, and TC with SPC but excluding patients with TC as SPC. Survival was
similar in the first 10 years after diagnosis of TC because SPCs were diagnosed in the course of
time (median time to SPC 11y, Table 1). Later survival curves diverged with marked poorer
survival for patients with SPC other than TC compared to those without SPC. At 30 years of
follow-up about 80% of TC patients without SPC were alive, compared to about 40% for
patients with SPC. The top curve for patients who had TC as SPC was based on only 11 deaths.
The hazard ratio, adjusted for a number of variables, was 1.45 (95%CI: 1.25–1.67) for patients
with SPC other than TC compared to those without SPC.
Discussion
The present results on SPCs provide novel insight into possible differential development of
SPC after seminoma and non-seminoma, and on mortality related to SPC. While 9.4% of TC
patients developed a SPC, the percentage was higher in seminoma (11.6%) compared to non-
seminoma (6.7%), (P<0.0001) but the risk of SPC was marginally higher for non-seminoma
compared to seminoma. As the median diagnostic age of TC was 34 years and the median fol-
low-up time was 11 years, a large proportion of patients were diagnosed with SPC before age
50 years. It is curious that the diagnosed SPCs, with the exception of second TC, were not typi-
cally mid-age cancers. Prostate cancer and five other typically late onset cancers accounted for
half of all SPCs after TC; their combined RR was 1.35 (95%CI: 1.21–1.49). Signs of early aging
in the form of ‘physiologic frailty’ have been described previously for childhood cancer survi-
vors [30, 31]. This was defined as a combination of low muscle mass, self-reported exhaustion,
low energy expenditure, slow walking speed, and weakness; this physiologic frailty was
Table 5. Cause of death in testicular cancer with or without second primary cancer.
Cause of death Without second primary cancer
Testicular cancer (N %) Seminoma (N %) Non-seminoma (N %)
Testicular cancer 291 (39.4) 80 (21.6) 173 (59.2)
Other cancers 61 (8.3) 27 (10.3) 20 (6.8)
Non-neoplastic 386 (52.3) 264 (71.2) 99 (33.9)
All 738 (100.0) 371 (100.0) 292 (100.0)
Cause of death With second primary cancer
Testicular cancer (N %) Seminoma (N %) Non-seminoma (N %)
Testicular cancer1 14 (4.6) 8 (3.5) 6 (8.3)
SPC2 non-testicular cancer 158 (52.3) 118 (52.2) 39 (54.2)
Higher order primary 19 (6.3) 15 (6.6) 4 (5.6)
Other cancers 40 (13.2) 28 (12.4) 11 (15.3)
Non-neoplastic 71 (23.5) 57 (25.2) 12 (16.7)
All 302 (100.0) 226 (100.0) 72 (100.0)
TC1 = testicular cancer, including first primary cancer and second primary cancer. SPC2 = second primary cancer.
https://doi.org/10.1371/journal.pone.0214410.t005
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associated with risk of death. In childhood leukemia survivors, evidence of cellular aging was
shown by leukocyte telomere length measurements which matched lengths for 20 years older
healthy individuals [32]. Many signs of physiologic aging have been also recorded for TC
patients [21].
The current therapeutic principles for treatment of TC were adopted in the 1980s. The max-
imal follow-up times of the surviving patients now exceed three decades and it will be possible
to assess the full scope of SPCs in TC survivors, as reviewed [11, 21]. Evidence of an increased
risk of leukemias was observed first and it was also seen in the present study for all leukemia
and acute and chronic myeloid leukemia and acute lymphoid leukemia [23, 33]. Risks for all
leukemia and acute myeloid leukemia were higher in the long follow-up period (5+ years)
while risks for chronic myeloid leukemia and acute lymphoid leukemia were confined to the
early follow-up period. A group of experts concluded after reviewing the available data on
SPCs after TC that among solid tumors significantly increased risks were demonstrated, three-
to seven-fold risks of cancers of the kidney, thyroid, and soft tissue [21]. The conclusion was
based on patients receiving chemotherapy and who were compared to patients who underwent
Table 6. Causes of death in patients diagnosed with second primary cancer after testicular cancer.
Second primary cancer Total number of deaths Cause of death N (%)
TC1 SPC2 HOPC3 OC4 Non-neoplastic
Upper aerodigestive tract 9 0 5 (55.6) 0 3 (33.3) 1 (11.1)
Esophagus 8 0 8 (100.0) 0 0 0
Stomach 14 0 10 (71.4) 0 2 (14.3) 2 (14.3)
Colorectum 30 1 (3.3) 26 (86.7) 0 1 (3.3) 2 (6.7)
Liver 7 0 7 (100.0) 0 0 0
Pancreas 13 0 13 (100.0) 0 0 0
Lung 28 1(3.6) 23 (82.1) 1 (3.6) 3 (10.7) 0
Prostate 47 4 (8.5) 17 (36.2) 5 (10.6) 3 (6.4) 18 (38.3)
Testis 11 5 (45.5) 0 2 (18.2) 1 (9.1) 3 (27.3)
Kidney 12 0 5 (41.7) 1 (8.3) 1 (8.3) 5 (41.7)
Urinary bladder 21 1 (4.8) 9 (42.9) 5 (23.8) 1 (4.8) 5 (23.8)
Melanoma 8 0 3 (37.5) 1 (12.5) 0 4 (50.0)
Skin, squamous cell 12 0 0 0 1 (8.3) 11 (91.7)
Nervous system 12 1 (8.3) 8 (66.7) 0 1 (8.3) 2 (16.7)
Thyroid gland 4 0 1 (25.0) 0 1 (25.0) 2 (50.0)
Connective tissue 6 0 0 0 5 (83.3) 1 (16.7)
Non-Hodgkin lymphoma 13 0 4 (30.8) 0 4 (30.8) 5 (38.5)
Myeloma 5 0 4 (80.0) 0 0 1 (20.0)
Leukemia 15 0 11 (73.3) 2 (13.3) 1 (6.7) 1 (6.7)
Acute myeloid leukemia 6 0 5 (83.3) 0 1 (16.7) 0
Chronic myeloid leukemia 1 0 1 (100.0) 0 0 0
Acute lymphoid leukemia 2 0 1 (50.0) 1 (50.0) 0 0
Chronic lymphoid leukemia 2 0 1 (50.0) 1 (50.0) 0 0
CUP5 17 1 (5.9) 3 (17.6) 0 9 (52.9) 4 (23.5)
All 302 14 (4.6) 158 (52.3) 19 (6.3) 40 (13.2) 71 (23.5)
TC1 = testicular cancer, included first primary cancer and second primary cancer.
SPC2 = second primary cancer. HOPC3 = higher (3th, 4th) order primary cancer.
OC4 = other cancer (excluding second primary cancer and higher order primary cancer and testicular cancer).
CUP5 = cancer of unknown primary.
https://doi.org/10.1371/journal.pone.0214410.t006
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surgery alone [22]. Patients in our cohort also received radiotherapy and the risk for the above
cancers were increased along with five other non-TCs. RRs for kidney and thyroid cancers
were increased in the long follow-up period.
According to the literature, approximately 5% of men with TC run a risk of contralateral
TC, of which 1/3 are synchronous tumors, and 2/3 metachronous tumors [34]. However,
lower percentages of 2.1 to 2.5% have been found in other studies on unknown laterality [20].
The present figure was 2.1%, higher for seminoma (2.5%) than for non-seminoma (1.8%).
The RRs were also higher (23.30, 95%CI: 19.49–27.86) for seminoma compared to non-semi-
noma (11.61, 95%CI: 9.11–14.80). The risk for second TC was higher (25.51, 95%CI: 21.15–
30.77) in short (5+ year) follow-up compared to long follow-up (11.86, 95%CI: 9.51–14.79).
The reasons for high contralateral TC extending throughout the follow-up period are likely
to be related to common developmental history and risk factors. This is consistent with data
on precursor lesions of TC which arise and accumulate following aberrant fetal gonocyte
development and which may occur in both testicles [6, 7]. However, as the risks of second
TCs appeared to increase with follow-up time, interacting therapeutic and developmental
damage may drive such long-term risks. Nevertheless, such high risks warrant alertness in
the patient follow-up, even if the limited current data showed no survival disadvantage for
patients with TC as SPC.
In the survival analysis, we showed that at 30 years of follow-up about 80% of TC patients
without SPC were alive, compared to about 40% for patients with SPC. The most common
Fig 1. Follow-up time since diagnosis of testicular cancer (years). Survival probability of TC patients without SPC, TC patients with TC as SPC and TC patients with
SPC other than TC. Shading around the plots show 95%CIs. Men at risk at each time point are listed below the figure.
https://doi.org/10.1371/journal.pone.0214410.g001
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causes of death in TC patients without SPC were non-neoplastic causes claiming 52.3% of
deaths, compared to 39.4% for TC. The pattern for non-neoplastic causes was even stronger in
seminoma whereas in non-seminoma TC was the main cause of death. In TC with SPC, SPCs
were the main cause of death overall (52.3%), as well as in seminoma as in non-seminoma.
The type of SPCs influenced the causes of death such as patients with fatal cancer of the pan-
creas, esophagus and liver; all patients died of SPC. A Norwegian study on long-term survival
in TC patients reported excellent survival in the first decade followed by ‘accelerated decline’
during 15 to 30 years of follow-up which they ascribed to late effects of treatment without dis-
tinguishing SPCs [35].
Lack of data on treatment is the major limitation of the study. Even though the main treat-
ment guidelines have been standardized our inability to distinguish the group of patients
undergoing surgery only excludes the possibility for internal comparisons. Another limitation
is the late introduction of the TNM classification in the Cancer Registry at around 2003. As a
consequence, we could identify only less than 100 TC patients with SPC and stage data; for
half of them the SPC was TC. TNM classification is not extended to SPCs which does not
allow assessment of the possible lead time bias in SPC diagnosis.
In summary, during the median follow-up time of 11 to 13 years close to 10% of TC patients
were subsequently diagnosed with SPC. This had unfavorable prognostic consequences, partic-
ularly if the SPC was known to be a fatal first cancer. Curiously, about half of the identified
SPCs were typical late-onset cancers, which suggests that therapy had facilitated premature
aging. While therapy is likely to contribute to the risk of SPCs, the very high risks for second
TC likely have primarily embryonic origins. Second TCs were diagnosed in 2.1% of the
patients and the risks appeared to increase over follow-up time calling for a long-term manage-
ment plan for TC patients.
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